A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
Latest Information Update: 04 May 2021
Price :
$35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Head and neck cancer
- Focus Therapeutic Use
- 02 Oct 2019 Status changed from recruiting to completed.
- 15 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 03 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.